Figure legend
Figure 1. Receiver operating characteristic (ROC) curves for
predicting adverse events from voriconazole concentrati
Figure 2. Diagnostic goodness-of-fit plots for basic model (A1,
A2) and final model (B1, B2). A1 and B1, Observed concentrations versus
population-predicted concentrations; A2 and B2, Observed voriconazole
plasma concentrations versus individual-predicted concentrations; the
lines are the lines of unity y=x.
Figure 3. Diagnostic goodness-of-fit plots for basic model (C1,
C2) and final model (D1, D2). C1 and D1, conditional weighted residualsversus population-predicted concentrations; C2 and D2,
conditional weighted residuals versus time.
Figure 4. The median voriconazole Ctroughversus time profiles for 30 days based
on the optimal intravenous (right)
or oral (left) dosing regimen. The loading doses of TBIL-1, TBIL-2 and
TBIL-3 patients were 400 mg q12h, 200 mg q12h and 200 mg q12h for first
day, respectively. The maintenance doses of TBIL-1, TBIL-2 and TBIL-3
patients were 100 mg q12h (squares), 50 mg q12h (filled dots) or 100mg
qd (triangles) and 50 mg qd (hollow dots), respectively.